Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Fineline Cube May 9, 2026
Company Drug

European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance

Fineline Cube May 9, 2026
Company Deals

Shenzhen AXBio Closes USD 100 Million Series B Round for Sequencing Tech Expansion

Fineline Cube Jun 20, 2022

Shenzhen-based fourth-generation sequencing company Anxuyuan Biotechnology (shenzhen) Company Limited (AXBio) has reportedly secured close to...

Company Medical Device

Boston Scientific Launches Expect Airway Ultrasound Needle in China for Lung Cancer Diagnosis

Fineline Cube Jun 20, 2022

US-based Boston Scientific Corporation (NYSE: BSX) has announced the official market launch of its Expect...

Company Deals

Iomics Biosciences Secures RMB 100 Million for Proteomics and Spatialomics Expansion

Fineline Cube Jun 20, 2022

Beijing-based Iomics Biosciences Co., Ltd, a developer of gene sequencing and diagnostic equipment, has reportedly...

Company Drug

InnoCare and Keymed Biosciences’ CCR8-Targeted mAb CM369 Accepted by NMPA

Fineline Cube Jun 20, 2022

China-based InnoCare (HKG: 9969) and Keymed Biosciences Inc. (HKG: 2162) announced that an Investigational New...

Policy / Regulatory

CDE Releases 58th and 59th Batches of Chemical Generic Reference Preparations

Fineline Cube Jun 20, 2022

The Center for Drug Evaluation (CDE) has released the 58th and 59th batches of chemical...

Company Deals

Shenzhen’s LWPOCT Secures RMB 100 Million in Series A Round for CDMO Expansion

Fineline Cube Jun 20, 2022

Shenzhen-based medical devices and reagents manufacturer Shenzhen Living Water POCT Co., LTd (LWPOCT) has reportedly...

Company Drug

Henlius Biotech Begins Global Phase III Trial for Denosumab Biosimilar HLX14

Fineline Cube Jun 20, 2022

China-based Shanghai Henlius Biotech Inc. (HKG: 2696) has announced the first patient dosing in a...

Company Drug

Cellular Biomedicine Group’s C-CAR039 Receives NMPA Approval for B-Cell NHL Study

Fineline Cube Jun 20, 2022

China-based Cellular Biomedicine Group Inc. (CBMG), a private company following a merger deal in February...

Company Deals

Global Cord Blood Corp’s Cellenkos Gets FDA Nod for Myelofibrosis Trial

Fineline Cube Jun 20, 2022

Global Cord Blood Corporation (GCBC; NYSE: CO) announced receiving Investigational New Drug (IND) approval from...

Company Deals

Hangzhou Tongee Medical Closes RMB 100 Million Series B Round for Gastric Bypass Stent

Fineline Cube Jun 19, 2022

Hangzhou Tongee Medical Technology Co., Ltd, a Chinese device maker specializing in metabolic disease treatments,...

Policy / Regulatory

Scotland Reports First Case of ASHep-UA in Children, WHO Issues Guidelines

Fineline Cube Jun 19, 2022

Scotland recorded its first case of acute severe hepatitis of unknown etiology in children (ASHep-UA)...

Company Drug R&D

Walvax’s mRNA Vaccine AWcorna Shows Superior Immune Response in Phase III Trial

Fineline Cube Jun 19, 2022

Walvax Biotechnology Co., Ltd’s (SHE: 300142) mRNA vaccine against SARS-CoV-2, named AWcorna, has reached the...

R&D

Tianhe-2 Supercomputer Aids Drug Discovery with Deep-Learning Biosynthetic Tool

Fineline Cube Jun 19, 2022

China’s Tianhe-2 supercomputer, ranked among the top-10 fastest computers globally, has demonstrated potential in enhancing...

Company Deals

Shanghai Pharmaceuticals Licenses Benapenem and Plazomicin from Xuanzhu Bio for Greater China

Fineline Cube Jun 19, 2022

China-based pharmaceutical giant Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) announced a licensing agreement with compatriot...

Company Drug

Sichuan Meida’s Phentolamine Gains Priority Review for Pheochromocytoma Treatment

Fineline Cube Jun 19, 2022

The Center for Drug Evaluation (CDE) website indicates that Sichuan Meida Kangjiale Pharmaceutical Co., Ltd’s...

Company Drug

Mabwell’s 6MW3511 Accepted by NMPA for Advanced Solid Tumor Treatment

Fineline Cube Jun 19, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that a clinical trial filing for...

Medical Device

NMPA Approves 164 Medical Devices in May 2022, Including Medtronic and Boston Scientific Products

Fineline Cube Jun 19, 2022

The National Medical Products Administration (NMPA) approved a total of 164 medical devices for marketing...

Hospital Policy / Regulatory

Boao Lecheng Sees Surge in Drug Use and Medical Tourism Amid Global Partnerships

Fineline Cube Jun 19, 2022

The Boao Lecheng Medical Tourism Pilot Zone reported a significant increase in special drug and...

Company Drug

Takeda’s Obizur Accepted by China’s NMPA for Acquired Hemophilia A Treatment

Fineline Cube Jun 19, 2022

Takeda Pharmaceutical Co., Ltd’s (NYSE: TAK, TYO: 4502) China unit announced that a New Drug...

Company Drug

Sirnaomics’ STP705 Shows Promising Results in Skin Cancer Trial

Fineline Cube Jun 19, 2022

Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) announced the peer-reviewed publication of Phase IIa...

Posts pagination

1 … 657 658 659 … 662

Recent updates

  • Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma
  • European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance
  • CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline
  • Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis
  • Innovent Biologics Secures Third Breakthrough Therapy Designation for IBI363 in MSS/pMMR Colorectal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Company Drug

European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Company Drug

Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.